At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
BI 1467335drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Positron Emission Tomography Study in Healthy Male Subjects to Explore the Inhibition of Monoamine Oxidase B in the Brain After Multiple Oral Doses of BI 1467335 (Non-randomized, Open-label, Parallel-group Study)
In Brief
A Phase 1 clinical trial evaluating BI 1467335 for Healthy. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to baseline using \[11C\]-L-deprenyl-D2 PET tracer in healthy male subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJun 2019
Primary CompletionNov 2019
TodayJul 2026
First PostedApr 25, 2019
Enrollment StartJun 6, 2019
Primary CompletionNov 22, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.2 years ago
Interventions
BI 1467335drug
tablet